Myeloprotective Effects of Different Amifostine Regimens in Rabbits Undergoing High-Dose Treatment with 186Rhenium-(tin)1,1-Hydroxyethylidene Diphosphonate ( 186Re-HEDP)

Cancer Biotherapy and Radiopharmaceuticals

Volumn 18, Issue 6, 2003, Pages 887-893

  Brenner, Winfried ^a,b   Kampen, Willm Uwe ^b   Brümmer, Corinna ^b   Von Forstner, Corinna ^b   Zuhayra, Maaz ^b   Muhle, Claus ^b   Czech, Norbert ^b   Henze, Eberhard ^b  

^a UNIVERSITY OF WASHINGTON MEDICAL CENTER   (United States)

^b UNIVERSITY OF KIEL   (Germany)

Author keywords

186Re HEDP; Amifostine; Bone uptake; Myeloprotection

Indexed keywords

AMIFOSTINE; ANTIEMETIC AGENT; DEXAMETHASONE; ETIDRONIC ACID RE 186; RADIOPHARMACEUTICAL AGENT;

ANIMAL MODEL; ARTICLE; BONE MARROW TOXICITY; BONE METASTASIS; BONE PAIN; CANCER PALLIATIVE THERAPY; CELL PROTECTION; CONTROLLED STUDY; DRUG MEGADOSE; DRUG UPTAKE; FEMALE; LEUKOCYTE COUNT; NONHUMAN; PRIORITY JOURNAL; SCINTILLATION CAMERA; THROMBOCYTE COUNT; TREATMENT OUTCOME; URINARY EXCRETION; WHOLE BODY SCINTISCANNING;

EID: 0346308581     PISSN: 10849785     EISSN: None     Source Type: Journal    
DOI: 10.1089/108497803322702851     Document Type: Article

References (28)

1. Maxon HR, Schroder LE, Thomas SR, et al. Rhenium-186(Sn)HEDP for treatment of painful osseous metastases: Initial clinical experience in 20 patients with hormone-resistant prostate cancer. Radiology 1990;176:155.
2. Maxon HR, Schroder LE, Hertzberg VS, et al. Rhenium-186(Sn)HEDP for treatment of painful osseous metastases: Results of a double-blind crossover comparison with placebo. J Nucl Med 1991;32:1877.
3. Graham MC, Scher HI, Liu GB, et al. Rhenium-186-labeled hydroxyethylene diphosphonate dosimetry and dosing guidelines for the palliation of skeletal metastases from androgen-independent prostate cancer. Clin Cancer Res 1999;5:1307.
4. Kolesnikov-Gauthier H, Carpentier P, Depreux P, et al. Evaluation of toxicity and efficacy of Re-186-hydroxyethylidene diphosphonate in patients with painful bone metastases of prostate or breast cancer. J Nucl Med 2000;41:1689.
5. Bruland OS, Skretting A, Solheim OP, Aas M. Targeted radiotherapy of osteosarcoma using Sm-153-EDTMP. A new promising approach. Acta Oncol 1996;35:381.
6. Geldof AA, Rooij DE, Versteegh RT, et al. Combination Re-186-HEDP and cisplatin supra-additive treatment effects in prostate cancer cells. J Nucl Med 1999;40:667.
7. McCready R, Al-Deen A, Treleaven J, Dearnalay D. Response of skeletal metastases to high activities of Rhenium-186-HEDP. [abstr.] Eur J Nucl Med 1999;26:PS 642.
8. Sodicoff M, Conger AD, Pratt NE, Trepper P. Radioprotection by WR-2721 against long-term chronic damage to the rat parotid gland. Radiat Res 1978;76:172.
9. Wasserman T. Radioprotective effects of amifostine. Semin Oncol 1999;26(suppl. 7):89.
10. Bohuslavizki KH, Brenner W, Klutmann S, et al. Radioprotection of salivary glands by amifostine in high-dose radioiodine therapy. J Nucl Med 1998;39:1237.
11. Bohuslavizki KH, Klutmann S, Brenner W, et al. Salivary gland protection by amifostine in high-dose radioiodine treatment: Results of a double-blind placebo-controlled study. J Clin Oncol 1998;16:3542.
12. Bohuslavizki KH, Klutmann S, Jenicke L, et al. Salivary gland protection by S-2-(3-amino-propylamino)-ehtylphosphorotioic acid (amifostine) in high-dose radioiodine treatment: Results obtained in a rabbit animal model and in a double-blind multi-arm trial. Cancer Biother Radiopharm 1999;14:337.
13. Product information. Essex Pharma, Munich, Germany, 1999.
14. Brenner W, Kampen WU, von Forstner C, et al. High-dose treatment with Re-186-HEDP or Sm-153-EDTMP combined with amifostine in a rabbit model. J Nucl Med 2001;42:1545.
15. Brenner W, Kampen WU, Kampen AM, Henze E. Skeletal uptake and soft tissue retention of Re-186-HEDP and Sm-153-EDTMP in patients with metastatic bone disease. J Nucl Med 2001;42:230.
16. Patt HM, Tyree EB, Straube RL, Smith DE. Technical papers. Cystein protection against X irradiation. Science 1949;110:213.
17. Yuhas JM, Spellman JM, Culo F. The role of WR-2721 in radiotherapy and/ or chemotherapy. Cancer Clin Trials 1980;3:211.
18. Wassermann TH, Philips TL, Ross G, Kane LJ. Differential protection against cytotoxic chemotherapeutic effects on bone marrow CFUs by WR-2721. Cancer Clin Trials 1981;4:3.
19. Shaw LM, Bonner H, Lieberman R. Pharmacokinetic profile of amifostine. Semin Oncol 1996;23(suppl. 8): 18.
20. Capizzi RL. Amifostine: The preclinical basis for broad-spectrum selective cytoprotection of normal tissues from cytotoxic therapies. Semin Oncol 1996;23(suppl. 8):2.
21. Yuhas JM. Active versus passive absorption kinetics as the basis for selective protection of normal tissues by S-2-(3-aminopropylamino)-ethylphosphorotioic acid. Cancer Res 1980;40:1519.
22. Lewis C. A review of the use of chemoprotectants in cancer chemotherapy. Drug Safety 1994;11:153.
23. Tannehill SP, Mehta MP. Amifostine and radiation therapy: Past, present and future. Semin Oncol 1996;23 (suppl. 8):69.
24. Capizzi RL, Scheffler BJ, Schein PS. Amifostine-mediated protection of normal bone marrow from cytotoxic chemotherapy. Cancer 1993;72:495.
25. Investigator's Brochure: Amifostine. West Conshohocken, PA: U.S. Bioscience, 1997.
26. Klutmann S, Bohuslavizki KH, Kröger S, et al. A rabbit animal model to evaluate myeloprotective effects of amifostine in palliation therapy with Re-186-HEDP. [abstr.] Nuklearmedizin 2000;39:A89.
27. Attie MF, Fallon MD, Spar B, et al. Bone and parathyroid inhibitory effects of S-2(3-aminopropylamino)ethylphosphorothioic acid. J Clin Invest 1985;75:1191.
28. Hirschel-Scholz S, Caverzasio J, Bonjour J. Inhibition of parathyroid hormone secretion and parathyroid hormone independent diminution of tubular calcium reabsorption by WR-2721, a unique hypocalcemic agent. J Clin Invest 1985;76:1851.